Alkylating Antineoplastic Agents
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Also Known As:
Antineoplastic Agents, Alkylating; Alkylating Antineoplastic Drugs; Alkylating Antineoplastics; Alkylating Drugs, Antineoplastic; Antineoplastic Alkylating Agents; Antineoplastic Drugs, Alkylating; Antineoplastics, Alkylating; Antineoplastic Alkylating Drugs; Drugs, Antineoplastic Alkylating; Alkylating Agents, Antineoplastic
Networked: 8
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Neoplasms (Cancer)
12/01/1992
- " During the past decades conclusive evidence has accumulated that alkylating antineoplastic drugs (ADs) can cause cancer, most notably acute non-lymphocytic leukaemia, and that most ADs are reprotoxic. " 12/03/1990
- " Martinus Nijhoff Publishers, Boston) to confine treatments with alkylating antineoplastic agents to AT-deficient tumors, is discussed." 03/01/1982
- " The effect of WR 2721 on the response of tumors to radiation, antineoplastic alkylating drugs, and DNA binding agents was evaluated and compared to the degree of normal tissue protection provided by WR 2721 against these agents. " 10/15/1992
- " Thus, monitoring DNA single-strand breaks in the peripheral mononuclear blood cells of patients can help to evaluate the efficiencies of the cancer treatment as a composite of individual differences in resorption, metabolic activation and detoxification, and possibly some constitutional aspects of drug resistance to cyclophosphamide/cisplatin and probably to several other alkylating antineoplastic drugs. " 01/01/1991
- " In an effort to increase the efficacy of several antineoplastic alkylating agents (CDDP, L-PAM, CTX, or BCNU), we examined the effect of the modulator Fluosol-DA/carbogen in combination with a second modulator, either lonidamine or pentoxifylline, on the survival of FSaIIC tumor cells and of bone marrow CFU-GM from tumor-bearing C3H mice. "
|
2. | Stupor
|
3. | Sarcoma (Soft Tissue Sarcoma)
|
4. | Ehrlich Tumor Carcinoma
|
|
Related Drugs and Biologics